Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects
Launched by ASTRAZENECA · Sep 3, 2009
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Weight between 45 to 100 kg and a body mass index (BMI) between 19 to 28 kg/m2
- • Japanese males aged between 20 to 45 years old (young) and Japanese males or females aged between 65 to 80 years old (elderly)
- Exclusion Criteria:
- • History of previous or ongoing somatic or psychiatric disease/condition
- • Abnormalities in ECG that may interfere with interpretation of data.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fukuoka, , Japan
Patients applied
Trial Officials
Anders Neijber, MD, PhD
Study Director
AstraZeneca R&D Södertälje
Shunji Matsuki, MD, PhD
Principal Investigator
Kyusyu Clinical Phramacology Research Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials